MedTrace Logo

Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices

NCT03160703 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2019-06-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate and compare the stain build up of two stannous fluoride (SnF2) / sodium tripolyphosphate (STP) dentifrices of differing abrasivity levels, with a marketed standard fluoride dentifrice and a marketed SnF2 dentifrice.

Conditions

  • Extrinsic Dental Stain
  • Oral Hygiene

Interventions

OTHER

Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica

Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA\~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.

OTHER

Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)

Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA\~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.

OTHER

Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80

Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA\~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.

OTHER

Stannous fluoride (SnF2, 0.454%), RDA~120

Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA\~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-10
Primary Completion
2017-08-25
Completion
2017-08-25

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03160703 on ClinicalTrials.gov